Browsing Tag
ImmunityBio
3 posts
ImmunityBio targets U.S. BCG shortage with exclusive Tokyo-172 agreement and FDA pathway plan
BCG supply is still a U.S. bladder cancer bottleneck. ImmunityBio’s Tokyo deal could widen access, if regulators move with it.
ImmunityBio (NASDAQ: IBRX) secures Saudi FDA approval for ANKTIVA in BCG-unresponsive bladder cancer
ImmunityBio secures Saudi approval for ANKTIVA in NMIBC. Find out how this reshapes the company’s MENA strategy and immunotherapy ambitions.
ImmunityBio, BeiGene launch Phase 3 Trial to advance lung cancer immunotherapy
ImmunityBio, Inc. (NASDAQ: IBRX) has entered into a collaboration and supply agreement with BeiGene, Ltd., a global oncology…